| Literature DB >> 35592471 |
Xujun Chu1, Kang Du1, Yuwei Tang1, Xutong Zhao1, Meng Yu1, Yiming Zheng1, Jianwen Deng1, He Lv1, Wei Zhang1, Zhaoxia Wang1, Yun Yuan1,2, Lingchao Meng1,2.
Abstract
Objects: This study was intended to explore the characteristics of muscle magnetic resonance imaging (MRI) of patients with hereditary transthyretin amyloidosis (ATTRv amyloidosis) prospectively.Entities:
Keywords: MRI; amyloidosis; fatty infiltration; polyneuropathy; transthyretin
Year: 2022 PMID: 35592471 PMCID: PMC9112281 DOI: 10.3389/fneur.2022.851190
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Demographic and clinical characteristics of patients with ATTRv amyloidosis.
|
|
|
|
|
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 38/M | 72 | II | Lys35Asn | distal>proximal | PN+AN+C+E | 41 | 3.25 | 3.25 | 0 | 0.193 | NA |
| 2 | 43/M | 36 | II | Val30Met | distal>proximal | PN+C+AN+H | 37.5 | 3.75 | 3.25 | 0 | 1.505 | Neurogenic |
| 3 | 42/M | 12 | I | Gly83Arg | distal>proximal | PN+E+AN+C+CTS | 22 | 3.75 | 3.5 | 0.39 | 0.215 | Neurogenic |
| 4 | 59/M | 24 | I | Ser77Phe | distal>proximal | PN+C+AN+E | 17 | 1.5 | 1.5 | 0.76 | 1.145 | NA |
| 5 | 33/M | 0 | I | Ala36Pro | no weakness | PN+AN+C+CTS | 0 | 0 | 0 | 10.05 | 1.595 | Neurogenic |
| 6 | 27/M | 12 | I | Glu42Gly | distal>proximal | PN+AN+C+Cough | 30.5 | 1 | 1 | 1.4 | 1.4 | Neurogenic |
| 7 | 56/M | 36 | II | Val30Met | distal>proximal | PN+AN+C+Cough | 20.75 | 3.125 | 1 | 1.38 | 0 | Neurogenic |
| 8 | 48/F | 0 | I | Val30Leu | no weakness | PN+AN+C | 0 | 0 | 0 | 4.3 | 1.225 | Neurogenic |
| 9 | 60/M | 84 | III | Val30Met | distal>proximal | PN+AN+C | 38 | 4 | 4 | NR | 0 | Neurogenic |
| 10 | 58/M | 12 | I | Val30Met | proximal>distal | PN+AN+C | 4 | 0 | 0 | 1.415 | 1.52 | NA |
| 11 | 27/F | 6 | I | Gly47Arg | distal>proximal | PN+AN+C+E | 6 | 0.5 | 0 | 0.115 | 0.325 | Neurogenic |
| 12 | 26/M | 0 | I | Phe33Val | distal>proximal | PN+C+AN+E+Cough | 2 | 0 | 0 | 0.485 | 0.71 | Neurogenic |
| 13 | 55/F | 12 | II | Val30Met | distal>proximal | PN+AN+C+E+Cough+H | 21 | 3 | 3 | 2.8 | 0.655 | Neurogenic |
| 14 | 27/F | 12 | I | Val30Ala | distal>proximal | AN+PN+C+Cough | 12 | 0 | 0 | 1.725 | 4.28 | NA |
| 15 | 42/M | 12 | I | Gly83Arg | distal>proximal | PN+AN+C+E | 12 | 1 | 1 | 3.35 | 5.6 | Neurogenic |
| 16 | 43/M | 16 | I | Gly83Arg | distal>proximal | PN+AN+E | 20 | 2.5 | 2.5 | 0 | 0 | Neurogenic |
| 17 | 50/F | 24 | II | Val30Leu | proximal>distal | PN+AN+C+Cough | 42.5 | 2.5 | 2.5 | 0 | 0 | Neurogenic |
| 18 | 57/M | 12 | II | Asp38Val | distal>proximal | PN+AN+C | 11 | 1.5 | 0 | 0.5 | 6.325 | NA |
| 19 | 47/M | 48 | II | Ala97Ser | distal>proximal | PN+AN+C | 20 | 1 | 1 | 0.445 | 0.45 | Neurogenic |
| 20 | 45/M | 36 | II | Val30Leu | distal>proximal | PN+AN+C | 46.5 | 3.875 | 3.875 | 0.75 | 0.2 | Neurogenic |
AN, autonomic neuropathy; ATTRv amyloidosis, hereditary transthyretin amyloidosis; C, cardiopathy; CMAP, compound muscle action potential (mean values of bilateral nerves); CTS, carpal tunnel syndrome; E, eye; EMG, electromyography; F, female; H, hearing loss; LL, lower limbs; M, male; mo., months; NA, not available; NIS-LL (weakness): neuropathy impairment score of lower limbs weakness; PN, peripheral neurology.
Strength of ankle dorsiflexion muscles was dominated by tibialis anterior muscle; Strength of ankle plantar flexion muscles was dominated by gastrocnemius and soleus muscles; y, years.
Figure 1Fatty infiltration (bilateral mean values) at calf and thigh levels. Bilaterally symmetrical and diffused muscles on axial T1WI at the thigh level (A), at the calf level (B); the posterior compartments of muscles had severely fatty infiltration at the thigh level (C), at the calf level (D); patient 8 had more severe fatty infiltration of muscles at the thigh level (E, F). The average score of fatty infiltration for each muscle was shown in heat maps (G, H). GM, gluteus maximus; OI, obturator internus, OE, obturator externus; RF, rectus femoris; VL, vastus lateralis; VM, vastus medialis; VI, vastus intermedius; SA, Sartorius; AM, adductor magnus; AL, adductor longus; AB, adductor brevis; GR, gracilis; ST, semitendinosus; SM, semimembranosus, BFL, long head of biceps femoris; BFS, short head of biceps femoris; TA, tibialis anterior; EH, extensor hallucis longus, ED, extensor digitorum longus; PB, peroneus brevis; PL, peroneus longus; PO, popliteus; TP, tibialis posterior; FD, flexor digitorum longus; FH, flexor hallucis longus; SO, soleus; MG, medial head of gastrocnemius; LG, lateral head of gastrocnemius.
Figure 2Comparison of fatty infiltration at calf and thigh levels, and different muscles compartments. (A) The proportion of fatty infiltration scores at the calf level was higher than that of the thigh level with paired comparison; (B) at the thigh level, the posterior compartments of muscles had severely fatty infiltration compared with medial compartments (p < 0.05); (C) the posterior compartments of muscles were heavily fatty at the calf level compared with anterior and lateral compartments *, ***Significant correlation at 0.05, 0.001 level, respectively. (all p < 0.001).
Fatty infiltration scores of each patient.
|
|
|
|
|
| |
|---|---|---|---|---|---|
| Patient 1 | 3.0 ± 0 | 1.1 ± 0.9 | 1.9 ± 1.2 | 3.0 ± 0 | 3.0 ± 0 |
| Patient 2 | 1.3 ± 1.4 | 0.5 ± 0.8 | 0.8 ± 1.1 | 2.1 ± 1.1 | 0 |
| Patient 3 | 1.4 ± 0.5 | 0.7 ± 0.8 | 1.0 ± 0.8 | 1.7 ± 0.5 | 1.0 ± 0 |
| Patient 4 | 3.4 ± 0.5 | 2.8 ± 1.2 | 3.0 ± 1.0 | 3.7 ± 0.5 | 3.0 ± 0 |
| Patient 5 | 1.0 ± 1.0 | 1.9 ± 0.8 | 1.5 ± 1.0 | 0.9 ± 1.1 | 2.0 ± 0 |
| Patient 6 | 0.5 ± 1.2 | 0.1 ± 0.3 | 0.3 ± 0.8 | 0.9 ± 1.5 | 0 |
| Patient 7 | 0.2 ± 0.6 | 0 ± 0.1 | 0.1 ± 0.4 | 0.3 ± 0.8 | 0 |
| Patient 8 | 0 | 0.8 ± 0.6 | 0.4 ± 0.6 | 0 | 0 |
| Patient 9 | 4.0 ± 0 | NA | NA | 4.0 ± 0 | 4.0 ± 0 |
| Patient 10 | 1.3 ± 0.7 | NA | NA | 1.6 ± 0.8 | 1.0 ± 0 |
| Patient 11 | 0.1 ± 0.3 | NA | NA | 0.1 ± 0.4 | 0 |
| Patient 12 | 1.7 ± 0.5 | NA | NA | 1.9 ± 0.4 | 1.3 ± 0.6 |
| Patient 13 | 0.5 ± 0.9 | 0 | 0.2 ± 0.6 | 0.9 ± 1.1 | 0 |
| Patient 14 | 0.2 ± 0.4 | 0 | 0.1 ± 0.3 | 0.3 ± 0.5 | 0 |
| Patient 15 | 0.1 ± 0.3 | 0 | 0 ± 0.2 | 0.1 ± 0.4 | 0 |
| Patient 16 | 1.5 ± 0.9 | 0.6 ± 0.6 | 1.0 ± 0.8 | 2.1 ± 0.7 | 0.5 ± 0 |
| Patient 17 | 1.2 ± 0.5 | 1.4 ± 1.0 | 1.3 ± 0.8 | 1.5 ± 0.4 | 0.7 ± 0.6 |
| Patient 18 | 0 | 0 | 0 | 0 | 0 |
| Patient 19 | 0.6 ± 0.8 | 0.2 ± 0.5 | 0.4 ± 0.7 | 1.0 ± 0.8 | 0 |
| Patient 20 | 2.4 ± 0.5 | 0.8 ± 0.7 | 1.5 ± 1.0 | 2.1 ± 0.4 | 2.7 ± 0.6 |
NA, not available.
Only data on sixteen patients were available as four patients did not perform muscle MRI at thigh levels.
The fatty infiltration scores of individual muscles used a modified 0–5 Mercuri's point scale (.
Figure 3Correlations between parameters of muscle MRI and clinical data. (A) The fatty infiltration of calf muscles was positively correlated with the disease duration of weakness; (B) the fatty infiltration at the calf level and fatty infiltration of posterior compartments at the calf levels were positively correlated with NIS-LL (weakness); (C) the fatty infiltration of posterior compartments at the calf level was negatively correlated with the amplitude of the CMAP of tibial nerves; (D) the fatty infiltration of posterior compartments at the calf level was related to the strength of ankle plantar flexion muscles (NIS score); (E) the fatty infiltration scores of anterior compartments at the calf level was not related to the amplitude of the CMAP of common peroneal nerves; (F) the fatty infiltration of anterior compartments at the calf level was not related to the strength of ankle dorsiflexion muscles (NIS score). *, **Significant correlation at 0.05, 0.01 level, respectively.